Characterization of the human GARP (Golgi associated retrograde protein) complexTumor-associated alterations in caspase-14 expression in epithelial malignanciesGeorg Kelling (1866-1945): the root of modern day minimal invasive surgery. A forgotten legend?Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.Bcl-B expression in human epithelial and nonepithelial malignancies.Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.Gene therapy of ovarian cancer.Expression of Bcl-2 family member Bid in normal and malignant tissues.Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.Endometrial carcinoma presenting as vasculitic sensorimotor polyneuropathy.Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.Successful intrauterine intracardiac transfusion in monochorionic twins affected by parvovirus B19.Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.Actual management of ductal carcinoma in situ of the breast.Size Does Not Make the Difference: 3D/4D Transperineal Sonographic Measurements of the Female Urethra in the Assessment of Urinary Incontinence SubtypesPrimary pulmonary choriocarcinoma: case report and review of the literature.Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.Altered expression of progesterone receptor isoforms A and B in human eutopic endometrium in endometriosis patients.Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach.Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR.
P50
Q24301512-0B805B80-6033-4DE0-B920-68C41E2A3995Q28265179-0FBF751D-A0F3-4C94-9572-B276FEFE0436Q28299363-3B07496B-18A4-433D-910B-FF08BE0AD4A7Q34185403-7BC86A5D-BC0A-4B27-A605-79AA2D9F8547Q34224114-18873F45-F672-49CE-8AAE-71D2063EFAB8Q34473693-7FDAE6ED-16A1-47C7-8987-FBF691D264C8Q34733867-9DD10E3C-DFA3-42D0-9EA1-C08F8C6C00BEQ34997430-0C0341E7-00A4-4076-86A6-A843D17A3929Q35155614-29C4B494-2184-40B8-A75E-BF0C7E0B2D07Q35857189-5559FC84-ED64-4ACC-B68A-7735A285C973Q35910659-8DB481F9-8FEC-440C-96FF-DCAAF0177700Q36865053-86601FF1-255E-4FAC-83A2-DE5118093930Q36891796-67F30CC6-2F83-4A6C-BE64-D5DA218AFED1Q37313698-C0AD3DC8-DA9C-448B-9368-00A9010D75E2Q37406021-C63D9ACE-2678-46C9-85CB-8C0807D25481Q37471367-3FD6A3CF-2D7A-4DA1-9532-2DD123F8A7B9Q38022102-895ED647-6DFC-4C8A-9871-07435F90F750Q38333986-F534E31E-3643-494E-BC70-29B981357C5FQ39650265-E24E7C65-7F10-4E4B-9F34-3751990A9DB2Q39859373-E300AA45-1049-4B96-984F-5B476F9FB2EFQ39937212-0980E54A-D578-4B8A-8175-1B7D76BDEB02Q40377121-148B8501-DDB4-4609-90E0-A4C7B85AE461Q40602973-6791F47A-5109-4F3F-B97A-5F2EBCE4E780Q40804289-5516ABAD-60CF-487C-A4BF-344A23A1EBB1
P50
description
German gynaecologist
@en
German gynaecologist
@en-ca
German gynaecologist
@en-gb
academisch docent
@nl
deutscher Gynäkologe
@de
ginecólogo alemán
@es
أخصائي أمراض نسائية ألماني
@ar
name
Ivo Meinhold-Heerlein
@af
Ivo Meinhold-Heerlein
@ast
Ivo Meinhold-Heerlein
@br
Ivo Meinhold-Heerlein
@ca
Ivo Meinhold-Heerlein
@da
Ivo Meinhold-Heerlein
@de
Ivo Meinhold-Heerlein
@dsb
Ivo Meinhold-Heerlein
@en
Ivo Meinhold-Heerlein
@es
Ivo Meinhold-Heerlein
@et
type
label
Ivo Meinhold-Heerlein
@af
Ivo Meinhold-Heerlein
@ast
Ivo Meinhold-Heerlein
@br
Ivo Meinhold-Heerlein
@ca
Ivo Meinhold-Heerlein
@da
Ivo Meinhold-Heerlein
@de
Ivo Meinhold-Heerlein
@dsb
Ivo Meinhold-Heerlein
@en
Ivo Meinhold-Heerlein
@es
Ivo Meinhold-Heerlein
@et
prefLabel
Ivo Meinhold-Heerlein
@af
Ivo Meinhold-Heerlein
@ast
Ivo Meinhold-Heerlein
@br
Ivo Meinhold-Heerlein
@ca
Ivo Meinhold-Heerlein
@da
Ivo Meinhold-Heerlein
@de
Ivo Meinhold-Heerlein
@dsb
Ivo Meinhold-Heerlein
@en
Ivo Meinhold-Heerlein
@es
Ivo Meinhold-Heerlein
@et
P214
P227
P19
P21
P213
0000 0004 2049 823X
P214
P227
1045253553
P31
P569
1969-03-23T00:00:00Z
P735
P7859
viaf-305439880